Article Information
History
- June 1, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- James O’Sullivan1,
- Guy Bogaarts1,
- Philipp Schoenenberger4,
- Julian Tillmann4,
- David Slater1,
- Nima Mesgarani6,
- Eckhart Eule4,
- Timothy Kilchenmann1,
- Lorraine Murtagh5,
- Joerg Hipp5,
- Michael Lindemann1,
- Florian Lipsmeier1,*,
- Wei-Yi Cheng3,
- David Nobbs1 and
- Christopher Chatham2
- 1Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland
- 2Biomarkers & Translational Technology, Neuroscience & Rare Diseases, Pharma Research & Early Development, Roche Innovation Center NY
- 3Roche Innovation Center New York, Roche TCRC Inc., New York, USA
- 4Neuroscience Early Development, Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland
- 5Neuroscience & Rare Diseases, Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland
- 6Mortimer B. Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY 10027, United States
- ↵*corresponding author: florian.lipsmeier{at}roche.com